Manchester-based F2G Ltd has appointed Ralf Schmid as its new chief financial officer.
Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.
He moves to F2G from Nabriva Therapeutics, where he had been a member of the management board since the Austrian biopharmaceutical company’s inception in 2006.
Schmid first served as the firm’s chief financial officer, before becoming chief executive officer, and most recently held the dual post of chief operating officer and chief financial officer.
Ian Nicholson, chief executive of F2G, said: “Following our successful $60m financing, I am delighted to welcome Ralf to the F2G team.
“His strong track record in fundraising, M&A transactions and deal structuring will be invaluable as we continue to generate positive data from our clinical trials and position the company for success.”